Please check your internet connection and try again.
## Calcium Acetate
### Overview
Calcium acetate is a phosphate binder used to control hyperphosphatemia in patients with chronic kidney disease (CKD). It binds to dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate, which is then eliminated in the feces.
### Primary Indications
* Management of hyperphosphatemia in patients with end-stage renal disease (ESRD).
### Adult Dosing
* **Initial Dose:** 1330 mg (667 mg elemental calcium) orally with meals.
* **Titration:** Dosage should be adjusted based on serum phosphate levels. Doses can range from 667 mg to 3335 mg per meal.
* **Maximum Dose:** Individualize based on serum phosphate control and calcium levels. Prescribing information does not specify a strict maximum daily dose, but typical prescribed amounts are often up to ~2001 mg per meal. Monitor serum calcium levels closely.
### Pediatric Dosing
* Dosing in pediatric patients has not been established. Use is generally not recommended due to potential for aluminum toxicity from impurities in some formulations and risk of hypercalcemia.
### Dose Adjustments
* **Renal Impairment:** Not applicable as it is used in patients with ESRD.
* **Hepatic Impairment:** No specific dose adjustments are recommended.
### Contraindications
* Hypercalcemia.
* Hypersensitivity to calcium acetate.
* Conditions that may lead to hypercalcemia (e.g., metastatic bone disease, certain renal conditions).
### Adverse Effects
* **Common:** Hypercalcemia (most significant), constipation, nausea, vomiting, abdominal pain.
* **Serious:** Vascular calcification, hypophosphatemia.
### Key Drug Interactions
* **Tetracyclines and Fluoroquinolones:** Calcium acetate can decrease the absorption of these antibiotics. Separate administration by at least 2 hours (before or after).
* **Thyroid Hormones:** Calcium acetate may decrease absorption of levothyroxine. Separate administration by at least 4 hours.
* **Other Calcium-Containing Products:** Increased risk of hypercalcemia.
* **Vitamin D Analogs:** Increased risk of hypercalcemia.
### Monitoring
* **Serum Phosphate:** Monitor frequently to guide dose titration. Target levels are typically < 5.5 mg/dL.
* **Serum Calcium:** Monitor regularly (e.g., 3 times weekly initially, then weekly, then monthly) to prevent hypercalcemia.
* **Alkaline Phosphatase:** Monitor as an indicator of bone turnover.
### Clinical Pearls
* Administer **with meals** to effectively bind dietary phosphate.
* Monitor both serum phosphate and calcium levels closely; adjusting the dose to control phosphate may lead to hypercalcemia.
* Patients may require dose adjustments if dietary phosphate intake changes.
* Consider alternative phosphate binders if hypercalcemia or constipation is problematic.
---
*This information is for educational purposes and does not substitute for current prescribing information. Always consult the official drug monograph or product labeling for the most up-to-date and comprehensive details.*
